AXOGEN INC (AXGN)
US05463X1063 - Common Stock
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative...
AXGN Crosses Below Key Moving Average Level
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Axogen (NASDAQ:AXGN) just reported results for the fourth quarter of 2023.Axoge...
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
Commit To Buy Axogen At $7.50, Earn 15.2% Annualized Using Options
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release.
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative...
Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS
Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs....
Axogen (AXGN) Shares Cross Above 200 DMA
Axogen climbs 4% on guiding FY revenue above consensus (NASDAQ:AXGN)
Axogen (AXGN) reports preliminary unaudited Q4 and year-end revenue and highlights, with an expected Y/Y increase of 18% and 15% respectively.
Axogen CEO Karen Zaderej to retire (NASDAQ:AXGN)
Axogen announced that CEO Karen Zaderej plans to retire by January 2025.
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative...
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical...
Axogen Announces Promotions on Research and Development Team
Company Also Announces Departure of Angelo Scopelianos, Ph.D.
Axogen Announces Promotions on Research and Development Team
Company Also Announces Departure of Angelo Scopelianos, Ph.D....
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of Directors...
Axogen Breaks Above 200-Day Moving Average - Bullish for AXGN
Axogen has named Nir Naor CFO (NASDAQ:AXGN)
Axogen (AXGN) appoints Nir Naor as CFO, replacing Peter Mariani.
Axogen Announces Transition of Finance Team Leadership
Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth
Axogen Announces Transition of Finance Team Leadership
Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of Growth...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical...